The Australian market has shown resilience, with the ASX climbing back above the 7,800 points level despite mixed signals from Wall Street. In this context of sector-wide gains, penny stocks—though a somewhat outdated term—continue to hold relevance as they offer unique growth opportunities at lower price points. These smaller or newer companies can present significant potential when backed by strong financials, and in this article, we spotlight three such promising picks on the ASX.

Top 10 Penny Stocks In Australia

Click here to see the full list of 983 stocks from our ASX Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Bravura Solutions

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Bravura Solutions Limited develops, licenses, and maintains software applications for wealth management and funds administration across Australia, the United Kingdom, New Zealand, and other international markets with a market cap of A$977.29 million.

Operations: Bravura Solutions generates revenue through its software applications for wealth management and funds administration, with operations spanning Australia, the United Kingdom, New Zealand, and various other international markets.

Market Cap: A$977.29M

Bravura Solutions has recently demonstrated a significant turnaround, reporting a net income of A$61.24 million for the half-year ended December 31, 2024, compared to a loss in the previous year. Despite being dropped from the S&P/ASX Emerging Companies Index, it announced both ordinary and special dividends payable in April 2025. The company revised its revenue guidance upwards to between A$248 million and A$252 million for fiscal year 2025. With no debt and strong short-term asset coverage over liabilities, Bravura offers an attractive price-to-earnings ratio of 13.6x compared to the broader Australian market average of 17.1x.

• Jump into the full analysis health report here for a deeper understanding of Bravura Solutions.
• Understand Bravura Solutions' earnings outlook by examining our growth report.

SiteMinder

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: SiteMinder Limited develops, markets, and sells online guest acquisition platforms and commerce solutions for accommodation providers globally, with a market cap of A$1.07 billion.

Operations: The company generates revenue from its Software & Programming segment, amounting to A$203.65 million.

Market Cap: A$1.07B

SiteMinder Limited, with a market cap of A$1.07 billion, reported sales of A$104.45 million for the half-year ended December 31, 2024, up from A$91.72 million the previous year. Despite this revenue growth, the company remains unprofitable with a net loss of A$13.89 million and a negative return on equity of -39.38%. SiteMinder is debt-free and has not diluted shareholders over the past year; however, its short-term assets slightly fall short of covering its short-term liabilities by A$1.2 million. Analysts anticipate significant stock price appreciation potential despite current challenges in profitability and cash flow management.

• Unlock comprehensive insights into our analysis of SiteMinder stock in this financial health report.
• Explore SiteMinder's analyst forecasts in our growth report.

Zeotech

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Zeotech Limited is involved in the exploration and evaluation of mineral properties in Australia, with a market cap of A$135.32 million.

Operations: The company's revenue is derived from its exploration activities, totaling A$0.98 million.

Market Cap: A$135.32M

Zeotech Limited, with a market cap of A$135.32 million, is pre-revenue and focuses on mineral exploration in Australia. The company recently highlighted its low embodied carbon AusPozzTM metakaolin product in concrete trials, showcasing potential industry applications. Despite being debt-free and having short-term assets exceeding liabilities, Zeotech's financial position is challenged by limited cash runway and historical losses increasing at 13.3% annually over five years. The appointment of Shane Graham as Executive Director brings valuable expertise from the building materials sector, potentially aiding strategic growth initiatives amidst ongoing unprofitability concerns and negative return on equity of -22.7%.

• Click to explore a detailed breakdown of our findings in Zeotech's financial health report.
• Learn about Zeotech's historical performance here.

Where To Now?

• Explore the 983 names from our ASX Penny Stocks screener here.
• Seeking Other Investments? Uncover 10 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:BVS ASX:SDR and ASX:ZEO.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com